Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice

Le, Xiuning; Sakai, Hiroshi; Felip, Enriqueta; Veillon, Remi; Chiara Garassino, Marina; Raskin, Jo; B. Cortot, Alexis; Viteri, Santiago; Mazieres, Julien; F. Smit, Egbert; Thomas, Michael; T. Iams, Wade; Chul Cho, Byoung; Ryun Kim, Hye; Chih-Hsin Yang, James; Chen, Yuh-Min; D. Patel, Jyoti; M. Bestvina, Christine; Park, Keunchil; Griesinger, Frank; Johnson, Melissa; Gottfried, Maya; Britschgi, Christian; Heymach, John; Sikoglu, Elif; Berghoff, Karin; Schumacher, Karl-Maria; Bruns, Rolf; Otto, Gordon; K. Paik, Paul

doi:10.1158/1078-0432.ccr-21-2733

Public

Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice

Published in Clinical Cancer Research • Nov 17, 2021

Authors:

Xiuning Le

Hiroshi Sakai

Enriqueta Felip

Abstract

PURPOSE: Primary analysis of VISION showed tepotinib had durable clinical activity in patients with MET exon 14 (METex14) skipping non-small cell lung cancer (NSCLC). We present updated outcomes for clinically relevant subgroups. PATIENTS AND METHODS: This phase II, open-label, multi-cohort study of...

Subject

Medicine

Clinical Practice

Relevance (law)

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!